Search

Displaying results 501 - 510 of 4539 in total
  1. Drug

    Carisoprodol

    go.drugbank.com/drugs/DB00395
    Approved

    In January 2012, this drug was classified as a Schedule IV substance under the controlled substances act in several US states due to alarming rates of abuse [A176062, A176077] despite having a low potential … This drug is available by itself in an oral tablet or combined with aspirin, or in a fixed-dose combination with both aspirin and codeine [FDA label, F4060, F4069].

  2. Drug

    Sipuleucel-T

    go.drugbank.com/drugs/DB06688
    ApprovedInvestigational

    The treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014. … In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data). Sipuleucel-T is marketed under the brand name Provenge by Dendreon Corporation.

  3. Drug

    Zileuton

    go.drugbank.com/drugs/DB00744
    ApprovedWithdrawn

    The immediate release tablet of Zileuton has been withdrawn from the US market.

  4. Drug

    Typhoid Vi polysaccharide vaccine

    go.drugbank.com/drugs/DB10803
    ApprovedInvestigational

    It is an active immunization for the prevention of typhoid fever caused by S typhi and is approved for use in persons two years of age or older.

  5. Drug

    Magnesium hydroxide

    go.drugbank.com/drugs/DB09104
    ApprovedInvestigational

    Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium ...

    Mixtures: Up and Up Antacid Anti Gas, Up and Up Famotidine Complete
  6. Drug

    Eslicarbazepine acetate

    go.drugbank.com/drugs/DB09119
    ApprovedInvestigational

    Eslicarbazepine's mechanism of action is not well understood, but it is known that it does exert anticonvulsant activity by inhibiting repeated neuronal firing and stabilizing the inactivated state of

  7. Drug

    Tivozanib

    go.drugbank.com/drugs/DB11800
    ApprovedInvestigational

    It was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524]

  8. Drug

    Testosterone undecanoate

    go.drugbank.com/drugs/DB13946
    ApprovedInvestigational

    [L35970] It was developed via fatty acid esterification of testosterone in order to achieve orally administer testosterone.

  9. Drug

    Ixazomib

    go.drugbank.com/drugs/DB09570
    ApprovedInvestigational

    [A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US. … [A264319] It was later approved by Health Canada on August 3, 2016,[L51239] and by the EMA on November 21, 2016.

  10. Drug

    Hydroxyprogesterone caproate

    go.drugbank.com/drugs/DB06789
    Approved

    Hydroxyprogesterone caproate was previously marketed under the trade name Delalutin by Squibb, which was approved by the U.S.